Propanc Biopharma, Inc.

Latest News

Mar 12, 2026

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Root-Cause Attack. Chemo Sensitization. Safer Profile. MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical…

View All Press Releases

Mar 10, 2026

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 3, 2026

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Feb 18, 2026

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
Latest Publication Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts View All Publications
Blocking Tumor Support from Cancer-Associated Fibroblasts in Tumor Microenvironment
Trypsinogen and chymotrypsinogen: potent anti- tumor agents
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting